Many of our patients report feeling refreshed, energized, and rehydrated shortly after their first session
P., Albiero, M., Menegazzo, L., de Kreutzenberg, S
A more serious concern with long term GLP-1RA usage relates to the potential increased risk for PDAC due to promoting cellular proliferation
The researchers also noted that 23.5% (95% CI, 22.3-24.8) of people meeting FDA indications for tirzepatide reported using medications that may slow gastrointestinal motility, which could increase gastrointestinal adverse effects when combined with any GLP-1 receptor agonist
V.FordL
These include practical tips for managing potential side effects and optimizing your results